Prevalence of mutant BRAF v600e in the papillary thyroid carcinoma in patients from Kazakhstan and its correlation with clinical-morphological tumor characteristic

2018

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.14300/mnnc.2018.13079
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

раСПроСТраНЕННоСТЬ мУТаНТНоГо Braf V600E в ПаПИЛЛярНом раКЕ ЩИТовИдНой ЖЕЛЕЗЫ У ПаЦИЕНТов ИЗ КаЗаХСТаНа И ЕГо СвяЗЬ С КЛИНИКо-морФоЛоГИЧЕСКИмИ ХараКТЕрИСТИКамИ оПУХоЛИ а.Ш. Тлегенов 1 , Ж. абылайулы 1 , д. Г. адилбай 2 , Ж. Б. Елеубаева 2 , Г. Б. адильбаев 2 , Э. Б. Сатбаева 2 , С. в.Большакова 1 1 Казахский национальный медицинский университет им.С. д. асфендиярова, алматы, Казахстан 2 Казахский научно-исследовательский институт онкологии и радиологии, алматы, КазахстанThe BRAF V600E mutation is the most frequent somatic oncogenic event in adult patients with papillary thyroid carcinoma (PTC).This work set out to determine the prevalence of mutant BRAF and its correlations with clinical-morphological characteristics of PTC, and to examine feasibility of detection of BRAF V600E in fine-needle aspiration biopsy material in patients from Kazakhstan.A total of 92 consequent patients diagnosed and treated for PTC from January 2016 to July 2017 were enrolled.Serial tissue sections of formalin-fixed paraffin embedded tissues were stained with hematoxylin and eosin, and immunohistochemically with monoclonal antibodies specific to the BRAF V600E protein.Positive immunohistochemical reaction was registered in 67.4 % of cases.